Radiation therapy oncology: in regard to Fu et al., IJROBP 2000;48:7-16

Comment

MacDonald B Logie. Int J Radiat Oncol Biol Phys. 2002.

. 2002 Mar 15;52(4):1148.

doi: 10.1016/s0360-3016(01)02776-6.

No abstract available

Comment on

Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
Fu KK, Pajak TF, Marcial VA, Ortiz HG, Rotman M, Asbell SO, Coia LR, Vora NL, Byhardt R, Rubin P, et al. Fu KK, et al. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):577-88. doi: 10.1016/0360-3016(95)00080-I. Int J Radiat Oncol Biol Phys. 1995. PMID: 7790242 Clinical Trial.
Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. FU et al.).
Withers HR, Peters LJ. Withers HR, et al. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):1-2. doi: 10.1016/s0360-3016(00)00644-1. Int J Radiat Oncol Biol Phys. 2000. PMID: 10924964 No abstract available.
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. Fu KK, et al. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16. doi: 10.1016/s0360-3016(00)00663-5. Int J Radiat Oncol Biol Phys. 2000. PMID: 10924966 Clinical Trial.